EDGC announced on June 5 that the company has launched its liquid biopsy service at ASCO, which was held from May 31 to June 2 in Chicago.

Liquid biopsy is considered a non-invasive alternative to tissue biopsy to detect various information about tumors. The advantages are that tissue collection is not necessary, deviation is minimized, and precise guides are available for cancer treatment. It takes about 3 to 4 weeks for the test results.

EDGC has carried out business activities for sales of liquid biopsy service (EDGC S-CAN, EDGC F-CAN) and genetic variants testing service (RISKCARE Focus, BRCARE) to target global market.

You Jae-hyung, vice president of EDGC, said, “ASCO is the world’s largest pharmaceutical and bio event attended by clinical researchers and companies. We had business discussions with participating companies on partnership and future joint research.” “It was a great initial opportunity to launch EDGC’s liquid biopsy service to the global market”, he added.

Kwan Hyuk-jung, manager of EDGC’s bioinformatics team, said, “We had a look into technical trends of liquid biopsy of global companies such as Grail at ASCO. EDGC is sophisticating the liquid biopsy service continuously through optimizing test protocols and BI algorithms.”